All In Biotech

Free tool

FAERS Monitor: Erleada

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210951 or its brand name (Erleada, Apalutamide). Reports on generic versions are filed under their own applications.

Reports

12,037

Serious

7,475

62% of reports

Hospitalization

2,717

Death reported

1,541

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash1,336
  • fatigue1,240
  • death1,203
  • hot flush922
  • product dose omission issue450
  • asthenia443
  • diarrhoea421
  • dizziness376
  • arthralgia371
  • off label use365
  • fall354
  • decreased appetite330
  • prostatic specific antigen increased314
  • incorrect dose administered295
  • pruritus294

Reports by year received

View as table
YearReports
20151
20164
20175
2018363
2019838
20201,248
20211,023
20222,105
20231,761
20241,837
20251,811
20261,041

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,122 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
prostatic specific antigen increasedSignal31440.736.511,861
hot flushSignal92221.620.317,962
rashSignal1,3365.45.14,831
fatigueSignal1,2402.82.61,470
product dose omission issueSignal4502.72.4477
decreased appetiteSignal3302.52.2294
deathSignal1,2032.42.31,065
incorrect dose administeredSignal2952.32.0208
astheniaSignal4432.11.9245
fall3541.91.7142
arthralgia3711.61.475
pruritus2941.31.225
dizziness3761.31.229
diarrhoea4211.11.07
off label use3650.70.738

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.